FILE PHOTO: A pharmacist selects drugs inside her pharmacy in Bordeaux, France, September 15, 2015. REUTERS/Regis Duvignau
ZURICH (Reuters) - Drugs being re-purposed in hopes they will help against COVID-19 cost little to make but may prove challenging to produce in quantities needed for a pandemic, a drug pricing expert said.
"Any pharmaceutical company manufacturing any treatment currently in clinical trials against coronavirus needs a clear plan to upscale production massively," Andrew Hill, a University of Liverpool research fellow, told Reuters.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
